Brief: VectivBio Announces First Patient Dosed In Metabolic Balance Study Of Apraglutide
15/06/2021 12:42
June 15 (Reuters) - VectivBio Holding AG VECT.O :
* VECTIVBIO ANNOUNCES FIRST PATIENT DOSED IN METABOLIC
BALANCE
STUDY OF APRAGLUTIDE IN COLON-IN-CONTINUITY PATIENTS WITH SHORT
BOWEL SYNDROME WITH INTESTINAL FAILURE
* VECTIVBIO HOLDING AG - INITIAL READOUT OF 4-WEEK
INTESTINAL
ENERGY ABSORPTION DATA EXPECTED IN 1H22
Source text for Eikon: ID:nGNX9N9c47
Further company coverage: VECT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VectivBio Holding AG
See all newsBrief: Ironwood And VectivBio Announce Expiration Of Hart-Scott-Rodino Waiting Period For Proposed Acquisition Of VectivBio
Brief: Ironwood Pharmaceuticals Says If Deal Aborts, VectivBio To Pay Termination Fee
U.S. STOCKS ON THE MOVE-Pfizer, Zoom Video, American Airlines
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
U.S. STOCKS ON THE MOVE-NuScale Power Corp, Foot Locker, Greenhill